NMS-293
- Generic Name
- NMS-293
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Nerviano Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT06931626
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Nerviano Medical Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT06930755
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Phase 1
Active, not recruiting
- Conditions
- Diffuse GliomaGlioblastoma
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Nerviano Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT04910022
- Locations
- 🇺🇸
Mayo Clinic Hospital - Phoenix, Phoenix, Arizona, United States
🇺🇸University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Nerviano Medical Sciences
- Target Recruit Count
- 150
- Registration Number
- NCT04182516
- Locations
- 🇧🇬
MHAT Sveta Sofia EOOD (Department of medical oncology), Sofia, Bulgaria
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇧🇬MHAT - Dobrich AD (Department of medical oncology), Dobrich, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath